267 related articles for article (PubMed ID: 23819727)
1. Statins in cardiometabolic disease: what makes pitavastatin different?
Ginsberg H
Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S1. PubMed ID: 23819727
[TBL] [Abstract][Full Text] [Related]
2. Pitavastatin in cardiometabolic disease: therapeutic profile.
Masana L
Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S2. PubMed ID: 23819752
[TBL] [Abstract][Full Text] [Related]
3. Statin diabetogenicity: guidance for clinicians.
Ray K
Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S3. PubMed ID: 23819776
[TBL] [Abstract][Full Text] [Related]
4. Pitavastatin: clinical effects from the LIVES Study.
Teramoto T
Atheroscler Suppl; 2011 Nov; 12(3):285-8. PubMed ID: 22152283
[TBL] [Abstract][Full Text] [Related]
5. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
6. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.
Nakajima K
Curr Clin Pharmacol; 2010 May; 5(2):133-9. PubMed ID: 20156152
[TBL] [Abstract][Full Text] [Related]
8. Pitavastatin and HDL: Effects on plasma levels and function(s).
Pirillo A; Catapano AL
Atheroscler Suppl; 2017 Jul; 27():e1-e9. PubMed ID: 28716185
[TBL] [Abstract][Full Text] [Related]
9. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
Miyares MA; Davis K
Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305
[TBL] [Abstract][Full Text] [Related]
10. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
[TBL] [Abstract][Full Text] [Related]
11. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
Kones R
Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
[TBL] [Abstract][Full Text] [Related]
12. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
13. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
14. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.
Ferdinand KC
J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832
[TBL] [Abstract][Full Text] [Related]
15. Pitavastatin - from clinical trials to clinical practice.
Masana L
Atheroscler Suppl; 2010 Dec; 11(3):15-22. PubMed ID: 21193154
[TBL] [Abstract][Full Text] [Related]
16. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
da Silva PM
Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
[TBL] [Abstract][Full Text] [Related]
17. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals.
Saito Y
Vasc Health Risk Manag; 2009; 5():921-36. PubMed ID: 19997573
[TBL] [Abstract][Full Text] [Related]
18. Raising HDL-C can be achieved by both lifestyle changes and pharmacological means. Introduction.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):265-6. PubMed ID: 22272435
[TBL] [Abstract][Full Text] [Related]
19. Statins for treatment of dyslipidemia in chronic kidney disease.
Shurraw S; Tonelli M
Perit Dial Int; 2006; 26(5):523-39. PubMed ID: 16973506
[TBL] [Abstract][Full Text] [Related]
20. Pitavastatin: an overview.
Saito Y
Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
